Back to all studies
CompletedNCT00044044

Three Dose Levels of SM-13496 Compared to Placebo and Haloperidol for schizophrenia

This study is completed in the United States. It is testing Three Dose Levels of SM-13496 Compared to Placebo and Haloperidol for schizophrenia.

SchizophreniaDrugFrom 18 Years to 64 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether the Efficacy and Safety of Three Dose Levels of SM-13496 Compared may be useful for adults experiencing schizophrenia.

What would participation involve?

Participants may receive the Efficacy and Safety of Three Dose Levels of SM-13496 Compared, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in the United States.

Who is it mainly for?

This study appears to be mainly for adults with schizophrenia.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)
  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateJuly 2002
Recruitment status
Completed
Enrollment listed in the registry
356
Sponsor
Sumitomo Pharma America, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 64 Years
Official registry ID
NCT00044044
Official title
A 6-Week, Double-Blind, Randomized, Fixed-Dose, Parallel-Group Study of the Efficacy and Safety of Three Dose Levels of SM-13496 Compared to Placebo and Haloperidol in Patients With Schizophrenia Who Are Experiencing an Acute Exacerbation of Symptoms

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT00044044. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

United States · 34 sites
  • Birmingham Psychiatry Pharmaceutical
    Birmingham, Alabama
    Site status: Not listed — confirm with the team
  • Institute for Psychopharmacology Research
    Cerritos, California
    Site status: Not listed — confirm with the team
  • CNS Network
    Garden Grove, California
    Site status: Not listed — confirm with the team
  • California Clinical Trials Medical Group
    Glendale, California
    Site status: Not listed — confirm with the team
  • Optimum Health Services
    La Mesa, California
    Site status: Not listed — confirm with the team
  • University of California, Irvine
    Orange, California
    Site status: Not listed — confirm with the team
  • Affiliated Research Institute
    San Diego, California
    Site status: Not listed — confirm with the team
  • Sharp Mesa Vista Hospital
    San Diego, California
    Site status: Not listed — confirm with the team
  • California Neuropsychopharmacolgoy Clinical Research Insitute
    San Diego, California
    Site status: Not listed — confirm with the team
  • Comprehensive Neuroscience. Inc.
    Washington D.C., District of Columbia
    Site status: Not listed — confirm with the team
  • Comprehensive Neuroscience. Inc.
    Melbourne, Florida
    Site status: Not listed — confirm with the team
  • Segal Institute for Clinical Research
    North Miami, Florida
    Site status: Not listed — confirm with the team
  • University of South Florida
    Tampa, Florida
    Site status: Not listed — confirm with the team
  • Coordinated Research of Florida, Inc.
    Winter Park, Florida
    Site status: Not listed — confirm with the team
  • Atlanta Center for Medical Research
    Atlanta, Georgia
    Site status: Not listed — confirm with the team
  • Carman Research
    Smyrna, Georgia
    Site status: Not listed — confirm with the team
  • Hawaii Research Center
    Honolulu, Hawaii
    Site status: Not listed — confirm with the team
  • Alexian Brothers Behavioral Health Hospital
    Hoffman Estates, Illinois
    Site status: Not listed — confirm with the team
  • American Medical Research
    Oak Brook, Illinois
    Site status: Not listed — confirm with the team
  • Centers for Behavioral Health, LLC
    Rockville, Maryland
    Site status: Not listed — confirm with the team
  • Lake Mead Hospital
    North Las Vegas, Nevada
    Site status: Not listed — confirm with the team
  • Comprehensive Clinical Research CNS, PC
    Clementon, New Jersey
    Site status: Not listed — confirm with the team
  • ClinSearch, Inc.
    Kenilworth, New Jersey
    Site status: Not listed — confirm with the team
  • Psychiatric Professional Services Inc
    Cincinnati, Ohio
    Site status: Not listed — confirm with the team
  • Quantum Clinical Services Group
    Philadelphia, Pennsylvania
    Site status: Not listed — confirm with the team
  • Albert Einstein Medical Center - Dept. of Psychiatry
    Philadelphia, Pennsylvania
    Site status: Not listed — confirm with the team
  • Community Clinical Research
    Austin, Texas
    Site status: Not listed — confirm with the team
  • FutureSearch Trials
    Austin, Texas
    Site status: Not listed — confirm with the team
  • Claghorn Lesem Research Clinic, Inc.
    Bellaire, Texas
    Site status: Not listed — confirm with the team
  • St. Paul Medical Center
    Dallas, Texas
    Site status: Not listed — confirm with the team
  • University Hills Clinical Research
    Dallas, Texas
    Site status: Not listed — confirm with the team
  • CNS, Inc.
    Falls Church, Virginia
    Site status: Not listed — confirm with the team
  • Northwest Clinical Research Center
    Belleview, Washington
    Site status: Not listed — confirm with the team
  • Medstream, Inc.
    Milwaukee, Wisconsin
    Site status: Not listed — confirm with the team
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving Lurasidone 20 mg, Lurasidone 40mg, Lurasidone 80 mg, Haloperidol 10mg, Placebo. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.

Who might this study be for?

This study may concern people with schizophrenia; age range: From 18 Years to 64 Years. The criteria appear strict, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Sumitomo Pharma America, Inc., which appears to be a pharmaceutical company. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me